Nov. 8, 2013
/PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced the publication of a case study, "Serial Sharp Debridement and Formulated Collagen Gel to Treat Pressure Ulcers in Elderly Long-term Care Patients", in the peer-reviewed
issue of Ostomy Wound Management
Ostomy Wound Manage
. 2013;59(11):43–49. The electronic publication of the study is available at
. The paper highlights Excellagen's capability of promoting rapid granulation and healing in chronic pressure ulcers in elderly long-term care facility residents.
The study involved patients with chronic, non-healing pressure ulcers of over 18 months duration, despite the use of a variety of treatments, including negative pressure wound therapy. The weekly treatment regimen consisted of sharp debridement and application of Cardium's advanced wound care product, Excellagen. All patients studied exhibited significant formation of new granulation tissue within their previously non-healing pressure wounds, which led to either complete wound closure or substantial wound reduction within 5 to 6 weeks of treatment. The study also gathered feedback from the study nurses via questionnaire. The study nurses agreed that weekly use of Excellagen "required less time and was more compatible with their busy schedules than standard care of daily (or multiple times daily) dressing changes."
The study's co-author,
Jennifer K. Agosti, RN
, Certified Wound Care Associate and Certified Foot and
Nail Care Nurse
, and the President of Nurse Sharks, Inc., a company focused on wound care management and infection control in long-term care facilities, stated, "I was impressed with the response to Excellagen and the dramatic speed of granulation tissue growth in these chronic wounds which had not responded to multiple other treatment interventions for over 18 months. We believe Excellagen is a potential cost-effective therapy for the treatment of pressure ulcers and although not included in the paper, we calculated that the total costs of the previous year of treatment in these patients compared to Excellagen ranged between
$10,800 and $16,500
Lois A. Chandler
, PhD, Cardium's Vice President, Biologics Development and co-author of the article, stated "We appreciate the contributions of the team at Nurse Sharks and look forward to the opportunity to work together on ongoing and additional case studies for the treatment of non-healing pressure ulcers in long-term care patients. These complex and challenging wounds are generally difficult to heal, and long-term care facilities represent a setting where the cost- and resource-effectiveness of Excellagen can provide significant benefits to both the patient and the facility."
According to the Agency for Healthcare Research and Quality, more than 2.5 million people in the U.S. develop pressure ulcers, and approximately 60,000 patients die annually as a result of them. Lawsuits related to pressure ulcers total 17,000 annually and account for the most common claim after wrongful death. Despite best efforts to implement guidelines for the prediction and prevention of ulcers, the prevalence remains high in long-term care facility residents. In the acute care and long-term care settings, pressure ulcers affect more than one million patients and the annual costs of treating pressure ulcers are projected to be between
$1.3 billion and $6.8 billion
About Ostomy Wound Management
Ostomy Wound Management was founded in March of 1980 as "Ostomy Management." In 1985, the journal expanded its content and readership by embracing the overlapping disciplines of ostomy care, wound care, incontinence care, and related skin and nutritional issues, and became the premier journal of its kind. Ostomy Wound Management's readers include healthcare professionals from multiple disciplines and its readers benefit from contemporary and comprehensive review and research papers that are practical, clinically oriented, and cutting edge. Each published article undergoes a rigorous double-blind peer review by members of both the Editorial Advisory Board and the Ad-Hoc Peer Review Panel. More information is located at
Excellagen is a syringe-based, professional-use, pharmaceutically-formulated 2.6% fibrillar Type I bovine collagen homogenate that functions as an acellular biological modulator to activate the wound healing process and significantly accelerate the growth of granulation tissue. Excellagen's FDA clearance provides for very broad labeling including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/graft, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds. Excellagen is intended for professional use following standard debridement procedures in the presence of blood cells and platelets, which are involved with the release of endogenous growth factors. Excellagen's unique fibrillar Type I bovine collagen homogenate formulation is topically applied through easy-to-control, pre-filled, sterile, single-use syringes and is designed for application at only one-week intervals. Additional information about Excellagen is available at